Certolizumab pegol + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Cystitis, Interstitial
Conditions
Cystitis, Interstitial
Trial Timeline
Dec 15, 2015 → Jul 12, 2017
NCT ID
NCT02497976About Certolizumab pegol + Placebo
Certolizumab pegol + Placebo is a phase 3 stage product being developed by UCB for Cystitis, Interstitial. The current trial status is completed. This product is registered under clinical trial identifier NCT02497976. Target conditions include Cystitis, Interstitial.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04123795 | Phase 3 | Active |
| NCT02497976 | Phase 3 | Completed |
| NCT01091220 | Phase 1 | Completed |
| NCT00674362 | Phase 3 | Completed |
Competing Products
19 competing products in Cystitis, Interstitial
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ferumoxytol + Gadobutrol | Lipella Pharmaceuticals | Phase 1 | 25 |
| LP-10 | Lipella Pharmaceuticals | Phase 2 | 44 |
| LP-08 80mg + Normal saline + LP-08 20mg | Lipella Pharmaceuticals | Phase 2 | 44 |
| ASP3652 + Placebo | Astellas Pharma | Phase 2 | 52 |
| Mirabegron + Placebo | Astellas Pharma | Phase 3 | 77 |
| ONO-1110 + Placebo | Ono Pharmaceutical | Phase 2 | 52 |
| Placebo + JNJ-42160443 | Johnson & Johnson | Phase 2 | 52 |
| Pentosan polysulfate sodium 100 mg + Placebo + Pentosan polysulfate sodium 100 mg | Johnson & Johnson | Approved | 85 |
| BOTOX + Placebo for BOTOX | AbbVie | Phase 2 | 52 |
| Rocuronium | Merck | Approved | 85 |
| Cidofovir | Gilead Sciences | Pre-clinical | 22 |
| PD 0299685 at 15mg BID + PD 0299685 at 30mg BID + placebo for PD 0299685 | Pfizer | Phase 2 | 51 |
| Tanezumab + Tanezumab + Tanezumab + Tanezumab | Pfizer | Phase 2 | 51 |
| ERB-041 | Pfizer | Pre-clinical | 22 |
| PF-04383119 + Placebo | Pfizer | Phase 2 | 51 |
| moxifloxacin | Bayer | Phase 3 | 74 |
| Cipro (Ciprofloxacin, BAYQ3939) | Bayer | Pre-clinical | 20 |
| IW-3300 rectal foam + Placebo | Ironwood Pharmaceuticals | Phase 2 | 44 |
| MN-001 BID + MN-001 + Placebo | MediciNova | Phase 2 | 44 |